Systematic Review of Clinical and Economic Evidence for Primary Open- Angle Glaucoma Therapy with Tafluprost vs Travoprost
Background: According to WHO, the number of patients with glaucoma in the world ranges from 60.5 to 105 million people, and the number of such patients is also predicted to increase to 80 million. Out of 28 million blind people in the world almost one in five lost their sight due to glaucoma. The aim of this research is to conduct a systematic review of the clinical and economic evidence for the treatment of primary open-angle glaucoma with Tafluprost vs Travoprost. Methods: PubMed interface, MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, NICE databases were used as main searching sources of this study.
